Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
8 studies found for:    "methodist hospital" | Open Studies | "Intestinal Diseases" | United States, Texas | Houston
Show Display Options
Rank Status Study
1 Recruiting TAA-Specific CTLS for Solid Tumors (TACTASOM)
Conditions: Bladder Cancer;   Breast Cancer;   Colorectal Cancer;   Endometrial Cancer;   Gastric Cancer;   Head and Neck Cancer;   HCC;   Lung Cancer;   Melanoma;   Neuroblastoma;   Sarcoma (Osteo-, Synovial, Rhabdomyo-, Etc);   Pancreatic Cancer;   Prostate Cancer;   Renal Cell Carcinoma;   Thyroid Cancer
Intervention: Biological: TAA-Specific CTLs
2 Recruiting Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: Apremilast;   Drug: Placebo
3 Recruiting Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease
Condition: Crohn Disease
Interventions: Drug: GED-0301;   Drug: Placebo
4 Recruiting HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA
Conditions: Human Papillomavirus-Related Carcinoma;   Human Papillomavirus Positive Oropharyngeal Carcinoma;   Human Papillomavirus Positive Cervical Carcinoma;   Human Papillomavirus Positive Anal Carcinoma;   Human Papillomavirus Positive Vulvar Carcinoma;   Human Papillomavirus Positive Penile Carcinoma
Intervention: Genetic: HPV Specific T Cells
5 Recruiting PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
Condition: Colorectal Cancer
Interventions: Drug: FOLFOX (chemotherapy);   Other: 5 FUCMT (chemoradiation);   Procedure: surgery;   Procedure: magnetic resonance imaging or endorectal ultrasound
6 Recruiting A Prospective, Multi-center Registry for Patients With Short Bowel Syndrome
Condition: Short Bowel Syndrome
Intervention:
7 Recruiting S0820, Adenoma and Second Primary Prevention Trial
Condition: Colorectal Neoplasms
Interventions: Drug: Eflornithine placebo & sulindac placebo;   Drug: eflornithine & sulindac placebo;   Drug: Eflornithine placebo & sulindac;   Drug: Eflornithine plus sulindac
8 Recruiting A Study Assessing Perfusion Outcomes With PINPOINT® Near Infrared Fluorescence Imaging in Low Anterior Resection
Conditions: Rectal Cancer;   Rectosigmoid Cancer
Interventions: Device: PINPOINT;   Device: SPY Elite

Indicates status has not been verified in more than two years